Document Detail


L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas.
MedLine Citation:
PMID:  13678974     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Ovarian and uterine carcinomas are the most common cause of cancer-related deaths in gynecological malignant diseases. We aimed to assess whether the L1 adhesion molecule, an important mediator for cell migration for neural and tumour cells, is expressed in these carcinomas. METHODS: We investigated L1 expression by immunohistochemistry, RT-PCR, and Western blot analysis of tumour samples. Soluble L1 in the serum was detected by ELISA and immunoprecipitation. FINDINGS: We detected the L1 adhesion molecule in ovarian and uterine tumours in a stage-dependent manner. In a retrospective study L1 was found in 46 of 58 ovarian carcinomas and 20 of 72 uterine adenocarcinomas. L1 expression was an excellent predictor of poor outlook (p<0.00001). Patients with L1 positive uterine tumours were at high risk for progression even in the endometrioid-type tumours, which usually have a favourable prognosis. In uterine tumours, expression of L1 in curettage samples enabled us to identify aggressive tumours before the operation. Soluble L1 was specifically detected in serum samples from patients with ovarian and uterine tumours. ADAM10, which was implicated in previous studies as L1 sheddase, was expressed in tumours in which soluble L1 was present in the serum. INTERPRETATION: L1 is overexpressed in ovarian and uterine carcinomas and is associated with short survival. L1 can serve as a new marker for prediction of clinical outcome and could be helpful to identify patients with uterine tumours who are at high risk for recurrent disease. L1 expression and cleavage could promote dissemination of tumours by facilitating cell migration.
Authors:
Mina Fogel; Paul Gutwein; Sabine Mechtersheimer; Svenja Riedle; Alexander Stoeck; Asya Smirnov; Lutz Edler; Alon Ben-Arie; Monica Huszar; Peter Altevogt
Related Documents :
9062154 - Differential transforming growth factor-beta secretion in adenocarcinoma and squamous c...
593184 - Calcium and cancer.
10825134 - Clinical implications of expression of interleukin 8 related to angiogenesis in uterine...
12445244 - Uterine carcinosarcomas (malignant mixed mullerian tumors) are metaplastic carcinomas.
1871214 - Glandular excision in total glandular mastectomy and modified radical mastectomy: a com...
8460634 - Genetic linkage analysis in familial breast and ovarian cancer: results from 214 famili...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Lancet     Volume:  362     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-09-18     Completed Date:  2003-11-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  869-75     Citation Subset:  AIM; IM    
Affiliation:
Department of Pathology, Kaplan Hospital, Rehovot, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antigens, Neoplasm / analysis,  genetics
Blotting, Western
Cell Movement / genetics
Disease Progression
Female
Humans
Immunohistochemistry
Leukocyte L1 Antigen Complex / analysis*,  genetics
Middle Aged
Ovarian Neoplasms / diagnosis,  genetics,  metabolism*
Prognosis
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Survival Analysis
Survival Rate
Tumor Markers, Biological / genetics
Uterine Neoplasms / diagnosis,  genetics,  metabolism*
Chemical
Reg. No./Substance:
0/Antigens, Neoplasm; 0/Leukocyte L1 Antigen Complex; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to...
Next Document:  Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population.